2023 saw a cautious hope for Alzheimer ' s treatment but doubts remain

The US approved lecanemab to slow cognitive decline among people with early Alzheimer ' s, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality

Source: New Scientist - Health - December 22, 2023 Category: Consumer Health News Source Type: research